Evaluation of autoimmune biomarkers in vitiligo patients' serum

Main Article Content

Ekhlas A. K. Kanani
Awatif H. Issa
Khalil I. Al-Hamdi

Keywords

C-reactive protein (hsCRP) and C-reactive protein (CRP) in

Abstract

Background: Vitiligo is one of the diseases which its pathogenesis has not yet been clearly understood, however many studies underline this disease as an autoimmune. The majority of authority preferred the autoimmune origins due to the substantial correlations between vitiligo and other autoimmune disorders, as well as having autoantibodies. The presence of antinuclear antibodies in vitiligo patients appear to support an autoimmune involvement in the disease's etiology. Aim of the study: investigation the prevalence and significance of antinuclear antibodies ANAs, high sensitivity C-reactive protein (hsCRP) and C-reactive protein (CRP) in vitiligo patients compared with healthy subjects. Methods: Ninety sera specimens from (45 vitiligo patients with matched 45 healthy controls) were analyzed in this study for Euroline ANA profile 23 (IgG) , hsCRP and CRP tests. Results: There were statistically significant positive findings of ANA in vitiligo patients in comparsion with controls subjects. Anti-RP-155 was the most prevalent in patients. In addition to high positive findings of hsCRP and CRP tests related to patients than controls. Conclusion: The study supports a significant association between vitiligo and other autoimmune diseases. Identification and characterization of anti-nuclear autoantibodies in vitiligo patients considered vital indicators support the findings of the most other researches indicating this disease is an autoimmune disease, and can pave the way for identifying the extent possible incidence of other autoimmune diseases, to take the appropriate medical procedure to avoid the exacerbation of diseases. ANAs findings supported with high positive findings of hsCRP and CRP proteins that might have a role in vitiligo pathogenesis. 

Abstract 371 | pdf Downloads 150

References

1. Rodrigues M, Ezzedine K, Hamzavi I, Pandya A G, Harris J E, & Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. Journal of the American Academy of Dermatology. 2017; 77(1), 1-13. doi:10.1016/j. jaad.2016.10.048.
2. Elbuluk N, & Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatologic clinics. 2017; 35 (2), 117-128. doi:10.1016/j. det.2016.11.002.
3. Morrison B, Burden-Teh E, Batchelor J M, Mead E, Grindlay D, & Ratib S. Quality of life in people with vitiligo: a systematic review and
meta-analysis. British Journal of Dermatology. 2017; 177(6). doi:10.1111/bjd.15933.
4. Lee H, Lee M H, Lee D Y, Kang H Y, Kim K H, Choi G S, ... & Oh S H. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei medical journal. 2015; 56(3), 719-725.
5. Said‑Fernandez S L, Sanchez‑Domínguez C N, Salinas‑Santander M A, Martinez‑Rodriguez H G, Kubelis‑Lopez D E, Zapata‑Salazar N A, ... & Ocampo‑Candiani J. Novel immunological and genetic factors associated with vitiligo: A review. Experimental and therapeutic medicine. 2021; 21(4),1-1.
6. Boniface K, Seneschal J, Picardo M, & Taïeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clinical reviews in allergy & immunology. 2018; 54(1), 52-67.
7. Waterman E. A., Gawkrodger D J, Watson P F, Weetman A P, & Kemp E H. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. Journal of Investigative Dermatology. 2010; 130(1), 230-240.
8. Wu C S, Lan C C, & Yu H S. Narrow‐band UVB irradiation stimulates the migration and functional development of vitiligo‐IgG antibodies‐treated pigment cells. Journal of the European Academy of Dermatology and Venereology. 2012; 26(4), 456-464.
9. Aydıngöz I E, Kanmaz‐Özer M, Gedikbaşi A, Vural P, Doğru‐Abbasoğlu S, & Uysal M. The combination of tumour necrosis factor‐α− 308
A and interleukin‐10− 1082 G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo. Clinical and experimental dermatology. 2015; 40(1), 71-77.
10.Lotti T, Hercogova J, & Fabrizi G. Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy. Expert opinion on Pharmacotherapy. 2015; 16(16), 2485-2496.
11.Arbuckle M R, McClain M T, Rubertone M V, Scofield R H, Dennis G J, James J A, & Harley J B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England Journal of Medicine. 2003; 349(16), 1526-1533.
12.Mok C C, Birmingham D J, Ho L Y, Hebert L A, Rovin B H. High-sensitivity C-reactive protein, disease activity, and cardiovascular
risk factors in systemic lupus erythematosus. Arthritis Care Res (Hoboken).2013; 65, 441– 7.
13.Barnes E V, Narain S, Naranjo A, Shuster J, Segal M S, Sobel E S, ... & Richards H B. High sensitivity C-reactive protein in systemic lupus
erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus. 2005; 14(8), 576-582.
14.Sur L M, Floca E, Sur D G, Colceriu M C, Samasca G, & Sur G. Antinuclear antibodies: marker of diagnosis and evolution in autoimmune diseases. Laboratory medicine. 2018; 49(3), e62-e73.
15.Nihtyanova S I, & Denton C P. Autoantibodies as predictive tools in systemic sclerosis. Nature reviews rheumatology. 2010; 6(2),
112-116.
16.Noble, P. W., Bernatsky, S., Clarke, A. E., Isenberg, D. A., Ramsey-Goldman, R., & Hansen, J. E. (2016). DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nature Reviews Rheumatology, 12(7), 429-434.
17.Im S R, Im S W, Chung H Y, Pravinsagar P, & Jang Y J. Cell-and nuclear-penetrating antidsDNA autoantibodies have multiple arginines
in CDR3 of VH and increase cellular level of pERK and Bcl-2 in mesangial cells. Molecular Immunology.2015; 67(2), 377-387.
18.Zaichik A S, Churilov L P, & Utekhin V J. Autoimmune regulation of genetically determined cell functions in health and disease. Pathophysiology. 2008; 15(3), 191- 207.
19.Pisetsky D S. Antinuclear antibody testing—misunderstood or misbegotten?. Nature Reviews Rheumatology. 2017; 13(8), 495-502.
20.Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte, T, Herold M, ... & Shoenfeld Y. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the rheumatic diseases. 2014; 73(1), 17-23.
21.Jacobe H, Sontheimer S D, Saxton-Daniels S. Autoantibodies encountered in patients with autoimmune connective tissue diseases. In: Bolognia J, Jorizo JL, Schaffer JV, ed. Dermatology. 2012; 3 ed: Elsevier, 607-609.
22.Martini A, Ravelli A, Avcin T, Beresford M W, Burgos-Vargas R. et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J. Rheumatol. 2019; 46, 190–197.
23.Tarvin S E, & O’Neil K M. Systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatric Clinics. 2018; 65(4), 711-737.
24.Mirouse A, Seror R, Vicaut E, Mariette X, Dougados M, Fauchais A.L, Deroux A, Dellal A, & Costedoat-Chalumeau N, Denis G, et al. Arthritis in primary Sj˝ogren’s syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. Autoimmun. 2019; Rev.18, 9–14.
25.Fernandez S A V, Lobo A Z C, Oliveira Z N P D, Fukumori L M I, Périgo A M, & Rivitti E A. Prevalence of antinuclear autoantibodies in
the serum of normal blood dornors. Revista do Hospital das Clínicas.2003; 58, 315-319.
26.Tebo A E. Recent approaches to optimize laboratory assessment of antinuclear antibodies. Clinical and Vaccine Immunology. 2017; 24(12), e00270-17.
27.Yumuk Z, & Demir M. Clinical value of antiDFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies testing. Journal of immunological methods. 2020; 480, 112754.
28.Aygün E, Kelesoglu F M, Dogdu G, Ersoy A, Basbug D, Akça D, ... & Ömeroglu R E. Antinuclear antibody testing in a Turkish pediatrics clinic: is it always necessary?. Pan African Medical Journal. 2019; 32(1).
29.Maki H, Kubota K, Hatano M, Minatsuki S, Amiya E, Yoshizaki A, ... & Komuro I. Erratum: Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. International Heart Journal. 2020; 61(3), 629- 629.
30.Yang Z, Ren Y, Liu D, Lin F, & Liang Y Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in S hanghai, China. APMIS. 2016; 124(9), 805- 811.
31.Arandia N I, Simeón-Aznar C P, Del Castillo A G, Argüelles D C, Rubio-Rivas M, Martínez L T, ... & Pla V F. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clin Exp Rheumatol. 2017; 35(Suppl 106), 98-105.
32.Sujau I, Ng C T, Sthaneshwar P, Sockalingam S, Cheah T E, Yahya F, etal. Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. International journal of rheumatic diseases. 2015; 18(4), 459-465.
33.Callejas-Moraga E L, Guillén-Del-Castillo A, Marín-Sánchez A M, Roca-Herrera M, Balada E, Tolosa-Vilella C, ... & Simeón-Aznar C P.
Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain. Clin Exp Rheumatol.2019; 37(Suppl 119), 41-8.
34.Richards M, García-De La Torre I, GonzálezBello Y C, Vázquez-Del Mercado M, et al. Autoantibodies to Mi-2 alpha and Mi-2 beta in
patients with idiopathic inflammatory myopathy. Rheumatology. 2019; 58(9), 1655-1661.
35.McHugh N J, & Tansley S L. myositis Ain. Autoantibodies in myositis. Nat Rev Rheumatol. 2018; 14, 290-302.
36.Carvalho M I C D P, & Shinjo S K. Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients withdermatomyositis. Advances in Rheumatology. 2019; 59.
37.Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, ... & Jia J. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary chol angiitis. Gastroenterology research and practice. 2019.
38.Hu S L, Zhao F R, Hu Q, & Chen W X. Metaanalysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One. 2014; 9(7), e101916.
39.Mytilinaiou M G, Meyer W, Scheper T, Rigopoulou E I, Probst C, Koutsoumpas A L, ... & Bogdanos D. P. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clinica Chimica Acta. 2012; 413(15-16), 1211-1216.
40.Bogdanos D P, & Komorowski L. Diseasespecific autoantibodies in primary biliary cirrhosis. Clinica chimica acta. 2011; 412(7-8), 502-512.
41.Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, ... & Canadian Scleroderma Research Group. Singlespecificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine. 2016); 95(35).
42.Aragón C C, González J D, Posso-Osorio I, Naranjo-Escobar J, Puerta G, Echeverri A, ... & Tobón G J. Anti-DFS70 antibodies: A new useful antibody in the exclusion of autoimmune diseases. Revista Colombiana de Reumatología (English Edition). 2018; 25(2), 104-111.
43.Infantino M, Nagy E, Bizzaro N, Fischer K, Bossuyt X, & Damoiseaux J. Anti -dsDNA antibodies in the classification criteria of systemic lupus erythematosus. Journal of Translational Autoimmunity. 2022; 5, 100139.
44.Dounya Bounid M D, Mohammed Oujidi M D, Soukaina Erradi MSc H T, & Brahim Admou M D. Clinical Significance of Anti-SS-A/ROantibodies. World Journal of pharmaceutical and medical reaserch. Wjpmr. 2021; 7(2), 06- 12.
45.Brito-Zerón P, Izmirly P M, Ramos-Casals M, Buyon J P, & Khamashta M A. The clinical spectrum of autoimmune congenital heart block. Nature Reviews Rheumatology. 2015; 11(5), 301-312.
46.Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. The Journal of dermatology.2010; 37(1), 42-53.
47.Margot A, Smet J, & Soyfoo S. Non-identified antinuclear antibodies in systemic sclerosis. Revue Medicale de Bruxelles. 2016; 37(5), 401-407.
48.Boonstra M, Mertens B J, Bakker J A, Ninaber M K, van der Helm-van Mil A H M, Scherer H U, ... & de Vries-Bouwstra J K. To what extent do autoantibodies help to identify high-riskpatients in systemic sclerosis?. Clinical and experimental rheumatology. 2018; 36(4), 109- 117.